MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH Has $13.98 Million Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH lowered its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.3% in the first quarter, HoldingsChannel reports. The fund owned 24,050 shares of the medical research company’s stock after selling 568 shares during the period. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH’s holdings in Thermo Fisher Scientific were worth $13,978,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the company. Dash Acquisitions Inc. boosted its stake in shares of Thermo Fisher Scientific by 3.9% in the 1st quarter. Dash Acquisitions Inc. now owns 26,851 shares of the medical research company’s stock valued at $14,694,000 after purchasing an additional 1,015 shares during the last quarter. Capital Advisors Ltd. LLC boosted its stake in Thermo Fisher Scientific by 2.4% in the first quarter. Capital Advisors Ltd. LLC now owns 1,212 shares of the medical research company’s stock valued at $704,000 after acquiring an additional 28 shares during the last quarter. Synergy Asset Management LLC grew its holdings in Thermo Fisher Scientific by 67.0% during the 1st quarter. Synergy Asset Management LLC now owns 5,198 shares of the medical research company’s stock worth $3,021,000 after acquiring an additional 2,085 shares during the period. Allspring Global Investments Holdings LLC lifted its stake in shares of Thermo Fisher Scientific by 40.5% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 125,565 shares of the medical research company’s stock valued at $72,980,000 after purchasing an additional 36,169 shares during the period. Finally, Oak Thistle LLC acquired a new position in Thermo Fisher Scientific in the first quarter valued at about $321,000. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Down 1.4 %

Shares of NYSE TMO traded down $7.79 during mid-day trading on Tuesday, hitting $533.93. The company had a trading volume of 1,315,042 shares, compared to its average volume of 1,549,182. Thermo Fisher Scientific Inc. has a one year low of $415.60 and a one year high of $603.82. The company has a market capitalization of $203.81 billion, a PE ratio of 34.32, a price-to-earnings-growth ratio of 2.58 and a beta of 0.77. The company has a current ratio of 1.70, a quick ratio of 1.33 and a debt-to-equity ratio of 0.68. The firm has a 50-day simple moving average of $574.71 and a two-hundred day simple moving average of $563.50.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, topping the consensus estimate of $4.70 by $0.41. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. The firm had revenue of $10.35 billion for the quarter, compared to analyst estimates of $10.14 billion. On average, equities analysts expect that Thermo Fisher Scientific Inc. will post 21.65 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, July 15th. Investors of record on Friday, June 14th will be issued a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 0.29%. The ex-dividend date of this dividend is Friday, June 14th. Thermo Fisher Scientific’s payout ratio is currently 10.01%.

Insider Buying and Selling

In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $572.41, for a total transaction of $5,724,100.00. Following the transaction, the chief executive officer now owns 123,816 shares in the company, valued at $70,873,516.56. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $572.41, for a total value of $5,724,100.00. Following the completion of the transaction, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $70,873,516.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Michael A. Boxer sold 2,000 shares of the company’s stock in a transaction dated Friday, April 26th. The stock was sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the sale, the senior vice president now directly owns 13,083 shares of the company’s stock, valued at approximately $7,430,359.02. The disclosure for this sale can be found here. In the last three months, insiders have sold 22,000 shares of company stock valued at $12,532,780. 0.34% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

TMO has been the topic of a number of analyst reports. HSBC increased their price target on shares of Thermo Fisher Scientific from $660.00 to $670.00 and gave the company a “buy” rating in a research report on Tuesday, April 30th. JPMorgan Chase & Co. lifted their price target on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a research report on Thursday, April 25th. The Goldman Sachs Group raised their price objective on Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Barclays decreased their target price on Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating for the company in a research note on Friday. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $650.00 price objective (up previously from $600.00) on shares of Thermo Fisher Scientific in a report on Monday, June 3rd. Five equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Thermo Fisher Scientific has an average rating of “Moderate Buy” and a consensus target price of $606.47.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.